Cancer immunotherapy drugs called immune checkpoint inhibitors take the brakes off the body’s immune system, allowing it to ...

UC San Diego researchers reveal key differences in PD-1 checkpoint receptors between rodents and humans. Rodent PD-1 is ...

Programmed cell death protein 1,” or PD-1, has been considered a key target in cancer therapies since its discovery in the ...

Since its discovery in the 1990s, "programmed cell death protein 1," or PD-1, has been regarded as a leading target in cancer treatments. A "checkpoint" receptor that often resides on the surface ...

Scientists have discovered significant discrepancies in PD-1 between humans and rodents, indicating that common lab models ...

GXP-1 is under clinical development by Egret Therapeutics and currently in Phase I for Transplant Rejection. According to GlobalData, Phase I drugs for Transplant Rejection have an 84% phase ...

Cell death terminates normal cellular functions, including respiration, metabolism, growth and proliferation. Cell death can be non-programmed ... gemcitabine and Mcl-1 inhibitor efficiently ...

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today annou ...

Westlake University in China and the California Institute of Technology have designed a protein-based system ... to stay alive or undergo programmed cell death. Cells naturally process multiple ...

Since its discovery in the 1990s, "programmed cell death protein 1," or PD-1, has been regarded as a leading target in cancer treatments. A "checkpoint" receptor that often resides on the surface of ...